SCHEMBL10134096

SCHEMBL10134096

O=C(O)c1ccc(Nc2ccc(-c3ccc4c(c3)CNC4=O)n3ccnc23)cc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK5 Q8IW41 4/20 0.48
GSK3B P49841 2/20 0.39
MKNK1 Q9BUB5 5/20 0.37
EIF4E P06730 1/20 0.37
MKNK2 Q9HBH9 1/20 0.37
DAPK3 O43293 1/20 0.37
NTRK1 P04629 1/20 0.37
PIM1 P11309 1/20 0.37
FLT3 P36888 1/20 0.37
ROCK1 Q13464 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
F9 P00740 1/20 0.37
SYK P43405 1/20 0.36
TNF P01375 1/20 0.36
TBK1 Q9UHD2 1/20 0.35
JAK2 O60674 1/20 0.35
TYK2 P29597 1/20 0.35
PRKCI P41743 1/20 0.35
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12618951 0.92 MAPKAPK5 (0.47) MAPKAPK5GSK3BMKNK1EIF4EMKNK2
SCHEMBL14162768 0.91 MAPKAPK5 (0.46) MAPKAPK5GSK3BMKNK1EIF4EMKNK2
SCHEMBL1685188 0.87 MAPKAPK5 (0.53) MAPKAPK5GSK3BMKNK1EIF4EMKNK2
SCHEMBL10134341 0.86 MAPKAPK5 (0.44) MAPKAPK5GSK3BDAPK3NTRK1PIM1
SCHEMBL14162585 0.86 MAPKAPK5 (0.44) MAPKAPK5GSK3BMKNK1EIF4EMKNK2
SCHEMBL1685240 0.84 MAPKAPK5 (0.41) MAPKAPK5GSK3BMKNK1EIF4EMKNK2
SCHEMBL1685248 0.83 MAPKAPK5 (0.42) MAPKAPK5GSK3BJAK2PIK3CAMTOR
SCHEMBL12618944 0.82 MAPKAPK5 (0.53) MAPKAPK5GSK3BMKNK1EIF4EMKNK2
SCHEMBL1685202 0.82 MAPKAPK5 (0.41) MAPKAPK5GSK3BTNFPIK3CAMTOR
SCHEMBL1685199 0.82 MAPKAPK5 (0.41) MAPKAPK5GSK3BTNFPIK3CAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed
WO-2008065199-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885GSK3B 2501/4885MKNK1 113/4885
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885GSK3B 2501/4885MKNK1 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.